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Abstract
Heparan sulfate is a highly sulfated polysaccharide that exhibits important physiological and 
pathological functions. The glucosamine residue of heparan sulfate can carry sulfo groups at the 2-
N-, 3-O- and 6-O- positions, leading to diverse polysaccharide structures. 6-O-sulfation at the 
glucosamine residue contributes to a wide range of biological functions. Here, we report a method 
to control the positioning of 6-O-sulfo groups in oligosaccharides. This was achieved by 
synthesizing oligosaccharide backbones from a disaccharide building block utilizing 
glycosyltransferases followed by modifications using heparan sulfate N-sulfotransferase and 6-O-
sulfotransferases. This method offers a viable approach preparing heparan sulfate oligosaccharides 
with precisely located 6-O-sulfo groups.
Heparan sulfate (HS) is a linear polysaccharide that is present on mammalian cell surfaces 
and in the extracellular matrix. HS is involved in numerous biological processes, including 
blood coagulation, wound healing, embryonic development and regulation of tumor growth, 
as well as in assisting viral and bacterial infections (1). The wide range of biological 
functions of HS attracts considerable interest in exploiting HS-based anticoagulant (2, 3), 
antiviral (4) and anticancer drugs (5). Heparin, a commonly used anticoagulant, is a highly 
sulfated form of HS. HS consists of repeating disaccharide units of glucosamine and 
glucuronic acid (GlcUA) or iduronic acid (IdoUA), both capable of carrying sulfo groups 
(Fig 1A). The positions of the sulfo groups and IdoUA dictate the functions of HS (6, 7).
The biosynthesis of HS is accomplished by a complex pathway involving backbone 
elongation and multiple modification steps. HS polymerase is responsible for building the 
polysaccharide backbone, which contains repeating units of –GlcUA-GlcNAc-. The 
backbone is then modified by N-deacetylase/N-sulfotransferase (which has two separate 
domains that exhibit N-deacetylation and N-sulfation, respectively), C5-epimerase (which 
converts GlcUA to IdoUA), 2-O-sulfotransferase, 6-O-sulfotransferase (6-OST) and 3-O-
sulfotransferase to produce the fully elaborated HS. Understanding this biosynthetic 
mechanism has advanced our ability to synthesize HS (8). Using HS sulfotransferases and 
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C5-epimerase, we developed a method to synthesize HS polysaccharides (2, 9, 10) and 
oligosaccharides with defined structures (11). Previously, a method for positioning N-sulfo 
glucosamine and IdoUA2S residues was demonstrated (11). It is still unknown whether or 
not placing a 6-O-sulfo group in a given oligosaccharide is possible.
The 6-O-sulfo glucosamine unit is a common monosaccharide in HS. It has been found that 
the 6-O-sulfo glucosamine residue plays a critical role in numerous biological functions. For 
example, heparin carrying 6-O-sulfo groups exhibits anti-inflammatory effects by blocking 
the binding of HS to L- and P-selectins (12). The 6-O-sulfated glucosamine residue was also 
found to regulate the fibroblast growth factor-mediated signaling pathway by binding to the 
fibroblast growth factor receptor (13, 14). 6-OST-1 knockout mice were shown to exhibit 
numerous defects. Most of the mice died at the embryonic and perinatal stages. Those that 
survived were significantly smaller in size than the wild type (15). These observations 
underscore the essential role of HS 6-OSTs in developmental physiology. In Drosophila, the 
removal of 6-OST genes has no obvious phenotype, suggesting the complex roles of 6-O-
sulfation in different organisms. Mutant strains of Drosophila have elevated levels of 2-O-
sulfation in response to the loss of 6-OST(16).
Little is known about how 6-O-sulfation patterns are regulated. HS 6-OSTs, which are 
present in three isoforms including 6-OST-1, -2 and -3 (17), catalyze the transfer of a sulfo 
group to the C6 position of a glucosamine residue (GlcN) to form 6-O-sulfo glucosamine 
(Fig 1B). Furthermore, HS 6-O-sulfatases remove 6-O-sulfo groups from HS in vivo and 
remodel HS structures (18,19). 6-O-sulfation occurs predominantly at N-sulfo glucosamine 
(GlcNS) residues. However, in some cases, it can also occur at the GlcNAc residues. Unlike 
different 3-O-sulfotransferase isoforms, 6-OST isoforms appear to recognize the same 
substrates (20), suggesting that a different strategy will be needed to introduce a 6-O-sulfo 
group in a specific position.
In this article, we report the placement of a 6-O-sulfo group at specific oligosaccharides 
using an enzymatic approach. We demonstrated the feasibility of selectively introducing a 6-
O-sulfo group using two distinct methods. First, by controlling the reaction time, we 
prepared partially 6-O-sulfated hexasaccharides although a mixture of two products was 
obtained. Second, we elongated the oligosaccharides already carrying 6-O-sulfo groups 
using glycosyltransferases. Our method provided a generic tool for synthesizing HS 
oligosaccharides with defined 6-O-sulfation patterns with which to elucidate the structure 
and activity relationship of HS. The results also aid our understanding of the substrate 
specificity of 6-OSTs.
Experimental Procedures
Expression and purification of HS biosynthetic enzymes
A total of five enzymes were employed for the synthesis of oligosaccharide substrates and 
for 6-O-sulfation, including N-acetyl D-glucosaminyl transferase from the E. coli K5 strain 
(KfiA), N-sulfotransferase (NST), 6-O-sulfotransferase 1 (6-OST-1), 6-O-sulfotransferase 3 
(6-OST-3) and heparosan synthase-2 (PmHS2) from Pasteurella multocida. All of these 
enzymes were expressed in E. coli using different fusion proteins as described previously (2, 
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21, 22). For 6-OST-1 and 6-OST-3, maltose-binding fusion proteins were used, and the 
fusion proteins were purified by an amylose column (New England Biolab). For NST, a 
glutathione S-transferase fusion protein was prepared and purified by a glutathione 
Sepharose column (GE Healthcare) (21). PmHS2 was expressed as an N-terminal fusion 
protein with a 6 × His-tag using a PET-15b vector (Novagen) (11). The expression of KfiA 
was carried out in BL21 star (DE3) cells (Invitrogen) coexpressing the bacterial chaperone 
proteins, GroEL and GroES.
Synthesis of a fluorous-tagged disaccharide (GlcUA-AnMan-Rf) and tagged 
oligosaccharide substrates
A disaccharide (GlcUA-AnMannose) was prepared from nitrous acid degraded heparosan as 
previously described omitting the NaBH4 reduction step (22). The resultant disaccharide 
was dialyzed against water using a 1000 molecular weight cut-off (MWCO) membrane 
(Spectrum). To introduce a fluorous-tag, the disaccharide was incubated with 2 equivalents 
of 4-(1H, 1H, 2H, 2H-perfluoropentyl) benzylamine hydrochloride (Fluorous Technologies) 
and NaBH3CN (10 equiv.) in MeOH overnight at room temperature. The resulting tagged 
disaccharide was purified by FluoroFlash column. Then, it was further purified by paper 
chromatography using Whatman 3 MM chromatography paper (Fisher) that was developed 
with 100% acetonitrile. Finally, the fluorous-tagged disaccharide (GlcUA-AnMan-Rf) was 
purified using a C18 column (0.46 × 25 cm, Thermo Scientific) under reverse phase HPLC 
(RP-HPLC) conditions. The column was eluted with a linear gradient from 90% solution A 
(0.1% TFA in water) to 50% solution A for 40 min at a flow rate of 0.5 mL/min, followed 
by an additional wash for 20 min with 100% solution B (0.1% TFA in acetonitrile) at a flow 
rate of 0.5 mL/min. The product was confirmed by electrospray ionization (ESI) mass 
spectrometry.
The fluorous-tagged hexasaccharides were synthesized from a fluorous-tagged disaccharide 
GlcUA-AnMan-Rf. To incorporate additional monosaccharides, we supplied the reaction 
mixture with either KfiA or PmHS2 and the appropriate UDP-monosaccharide donor. As a 
result, only one sugar residue was transferred to the backbone as described previously (11). 
A FluoroFlash column was used to separate the tagged oligosaccharides from the unreacted 
UDP-monosaccharides and enzymes. Briefly, fluorous silica gel (40 μm, Fluorous 
Technologies) was washed with water and eluted with methanol. The reaction cycle was 
repeated to prepare hexasaccharide substrates.
Preparation of UDP-GlcNTFA
UDP-GlcNTFA was synthesized using a chemoenzymatic approach as described previously 
(11). Briefly, 11 mg of GlcNH2-1-phosphate (Sigma-Aldrich) was dissolved in 200 μL of 
anhydrous methanol and mixed with 60 μL of (C2H5)3N and 130 μ L S-ethyl 
trifluorothioacetate (Sigma-Aldrich). The reaction was incubated at room temperature for 24 
h. The resultant GlcNTFA-1-phosphate was then converted to UDP-GlcNTFA using 
glucosamine-1-phosphate acetyltransferase/N-acetylglucosamine-1-phosphate 
uridyltransferase (GlmU) in a buffer containing 46 mM Tris-HCl (pH 7.0), 5 mM MgCl2, 
200 μM dithiothreitol, 2.5 mM UTP and 0.012 U/μL inorganic pyrophosphatase (Sigma-
Aldrich). Recombinant GlmU was expressed in E. coli and purified by a Ni-Agarose column 
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(22). The UDP-GlcNTFA was purified by removing proteins using centrifugal filters 
(10,000 MWCO, Millipore) followed by dialysis against water using a 1,000 MWCO 
membrane for 4 h. The product was confirmed by MS analysis. The concentration was 
determined by a quantitative analysis with PAMN-HPLC using UDP-GlcNAc as a standard.
Removal of the N-trifluoro group from GlcNTFA units
Various amounts of oligosaccharides (50 to 100 μg) were dried and re-suspended in a 
solution (500 μL) containing CH3OH, H2O and (C2H5)3N (v/v/v = 2:2:1). The reaction was 
incubated at 37 °C overnight. The samples were dried and reconstituted in H2O to recover 
de-N-trifluoroacetylated oligosaccharides.
Enzymatic preparation of N-sulfated and 6-O-sulfated oligosaccharides
For the N-sulfation step, the oligosaccharide substrate (20 to 30 μg) was incubated with NST 
(80 μg) and PAPS (2 equiv.) in 500 μL buffer containing 50 mM MES (pH 7.0) and 1% 
Triton X-100 overnight at 37 °C. After the reaction was incubated for 12 h, the sulfated 
oligosaccharide was purified by a C18 column (0.46 × 25 cm, Thermo Scientific) under 
reverse phase HPLC (RP-HPLC) conditions as described above. To prepare N-[35S]sulfated 
oligosaccharides, [35S]PAPS (1 to 5×106 cpm) was included in the reaction mixture. To 
prepare 6-O-sulfated oligosaccharides, a similar procedure was followed except for the 
replacement of NST with 6-OST-1 and 6-OST-3. The product was confirmed by 
electrospray ionization (ESI) mass spectrometry whenever sufficient amount of samples 
were prepared.
HPLC analysis
HPLC analyses of the oligosaccharides were carried out as previously described (2, 9,11).
Disaccharide analysis
The oligosaccharides were digested with a mixture of heparin lyases to yield disaccharides. 
The oligosaccharide (100,000 cpm) was incubated with a mixture of heparin lyase I, II, and 
III (each at about 20 μg) in 200 μL of 50 mM Na2HPO3, pH 7.0, at 37 °C for 48 h. 
Additional aliquots of heparin lyase I, II, III were added after 24 h. The recombinant heparin 
lyases were expressed and purified as described previously (23). The resultant disaccharides 
were analyzed using a reverse-phase ion pairing (RPIP)-HPLC method as described 
previously (24). The identities of the disaccharides were determined by coeluting with HS 
disaccharide standards (Seikagaku America).
Mass spectrometry (MS) analysis
MS analyses were performed on a Thermo LCQ-Deca. Oligosaccharides were dissolved in 
1:1 MeOH/H2O in 10 mM ammonium hydroxide. A syringe pump (Harvard Apparatus) was 
used to introduce the sample via direct infusion (30 μL/min) into the instrument. 
Experiments were performed in negative ionization mode with a spray voltage of 3.8 kV and 
a capillary temperature of 200 °C (25). The automatic gain control was set to 1 × 107 for full 
scan MS and 2 × 107 for MS/MS experiments. For MS/MS experiments, the selection of 
each precursor ion was achieved using an isolation width of 3 Da and the activation energy 
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was 45% normalized collision energy. The product ions in the MS/MS data were labeled 
according to Domon-Costello nomenclature (26). The MS and MS/MS data were acquired 
and processed using Xcalibur 1.3 software.
Results
Preparation of oligosaccharide substrates
Four oligosaccharide substrates 1-4 were synthesized for this study (Table 1). These 
oligosaccharides were prepared from a fluorous-tagged disaccharide precursor using 
bacterial glycosyltransferases, KfiA and PmHS2, as described under Experimental 
Procedures. The fluorous tag enabled us to purify the products in a single step using a 
fluorous flush column. The structures of both trisaccharide 1 and tetrasaccharide 2 were 
confirmed by ESI-MS (Table 1). To prepare the N-sulfated hexasaccharide 3 and 4, we 
utilized UDP-GlcNTFA as a monosaccharide donor followed by base treatment and N-
sulfotransferase modification as described in our prior publication (11). The ESI-MS 
analysis of both hexasaccharide 3 and 4 demonstrated that the hexasaccharides have 
molecular masses of 1422.5 and 1422.4, respectively. These molecular masses are very 
close to the calculated value of 1422.1, suggesting that both hexasaccharide 3 and 4 have six 
saccharide units and carry a single sulfo group (Fig 2A and 2B).
The locations of the sulfo group in each hexasaccharide was determined using tandem MS 
(MS/MS) (Fig 2C and 2D). For hexasaccharide 3, a daughter ion with an m/z value of 827.5 
was detected, which confirmed that the GlcNAc residue is the third residue from the 
reducing end (Fig 2C, Y3 fragment). We observed a daughter ion with an m/z value of 
622.0, demonstrating that the GlcNS residue is the fifth residue from the reducing end (Fig 
2D, Y 2-5 fragment). Likewise, for hexasaccharide 4, a daughter ion with an m/z value of 
865.3 was observed, which confirmed that the GlcNS residue is the third residue from 
reducing end (Fig 2D, Y3 fragment).
Synthesis of 6-O-sulfated trisaccharide and tetrasaccharide
Incubation of trisaccharide 1 with a mixture of 6-OST-1 and 6-OST-3 yielded 6-O-sulfated 
trisaccharide 5. Both ESI-MS analysis and tandem MS analysis confirmed the structure of 
the anticipated product (Fig 3A and 3C). The 6-O-sulfated tetrasacccharide 6 was prepared 
by incubating tetrasaccharide 2 with 6-OST-1 and 6-OST-3. Mass spectrometry analysis 
revealed the molecular mass of the 6-O-sulfated tetrasaccharide 6 to be 1084.8, which is 
close to the calculated mass of 1084.2 (Fig 3B). Tandem MS analysis confirmed the position 
of the GlcNAc6S residues in 6 (Fig 3D) from two characteristic daughter ions, Y3 (m/z, 
907.4) and B2 (m/z, 458.4), which are products of the cleavage of internal glycosidic 
linkages. Our results demonstrated that the mixture of 6-OST-1 and -3 are able to sulfate 
substrates as short as a trisaccharide. It should be noted that only ~40 % of the trisaccharide 
was converted to the 6-O-sulfated trisaccharide product even after extensive incubation, 
suggesting that the sulfation efficiency for a trisaccharide is low.
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Synthesis of 6-O-sulfated hexasaccharide
We tested whether a mixture of 6-OST-1 and - 3 preferably sulfate GlcNS residues using a 
hexasaccharide model substrate (hexasaccharide 3, Table 1). Exhaustive incubation of the 
substrate with 6-OSTs resulted in a major product, hexasaccharide 7. Analysis of the product 
by ESI-MS revealed its molecular mass to be 1582.2, which is close to the calculated 
molecular mass (1582.3 Da) for a trisulfated hexasaccharide (Supplementary Fig 1), 
suggesting that the product carried two 6-O-sulfo groups. The structure of this 6-O-sulfated 
hexasaccharide was further confirmed by a disaccharide analysis as described below. Our 
results suggest that the enzymes do not distinguish GlcNAc and GlcNS residues with 
exhaustive incubation. To compare whether 6-OST-1 alone vs. a mixture of 6-OST-1 and -3 
produce similar sulfation products, we incubated the enzymes with hexasaccharide 3 under 
two different concentrations of the sulfo donor, PAPS (Supplementary Fig 2). Under a low 
concentration of PAPS (0.7 μM), both 6-OST-1 and the mixture of 6-OST-1 and -3 yielded 
one major 35S-labeled hexsaccharide eluted at 35 min on DEAE-HPLC that is consistent 
with a singly 6-O-sulfated product; likewise, under a high concentration of PAPS (80 μM), 
the enzymes yielded a major 35S-labeled hexasaccharide eluted at 48 min on DEAE-HPLC 
that is consistent with the structure of hexasaccharide 7. Taken together, our data suggest 
that the substrate specificities of 6-OST-1 and the mixture of 6-OST-1 and -3 are 
indistinguishable. Thus, a mixture of 6-OST-1 and -3 was used to sulfate the 
oligosaccharides throughout the study unless otherwise is specified.
Next, we examined if selective 6-O-sulfation can be achieved under partial or limited 
sulfation conditions. To facilitate the detection, an N-[35S]sulfated hexasaccharide 3 was 
prepared, where a GlcNS residue is located closer to the nonreducing end. The 35S-labeled 
hexasaccharide was then modified by the mixture of 6-OST-1 and -3 for various amounts of 
time. The 6-O-sulfated hexasaccharide products were then analyzed by a DEAE-HPLC 
column (Fig 4). The starting N-sulfated hexasaccharide 3 had a retention time of 24 min (Fig 
4A). After a one-hour reaction time, a small but detectable 35S-labeled peak (Peak I) was 
observed at 35 min, suggesting that a 6-O-sulfated product was formed (Fig 4B). After four 
hours of reaction (Fig 4C), the intensity of Peak I increased, and another 35S-labeled peak 
(Peak II) emerged at 48 min, suggesting that the products contained two hexasaccharides 
carrying one and two 6-O-sulfo groups, respectively. After twenty-four hours of reaction 
(Fig 4D), only Peak II was observed, suggesting that the reaction was completed.
The structures of Peak I and Peak II were confirmed by disaccharide analysis. The result of 
the disaccharide analysis of Peak I revealed a single 35S-labeled disaccharide with a 
structure of μUA-[35S]GlcNS and a small but detectable amount of μUA-[N-35S]GlcNS6S 
(Fig 5A and 5B). This result suggests that the 6-O-sulfo group is predominantly absent on 
the GlcNS residue that is located closer to the nonreducing end, resulting in a 
nonradioactively-labeled disaccharide, μUA-GlcNAc6S. The results of the disaccharide 
analysis also suggest that Peak I is a mixture of two hexasaccharides carrying a single 6-O-
sulfo group, and the 6-O-sulfo group is mainly on the residue that is closer to the reducing 
end, i.e. on the GlcNAc residue. As expected, the disaccharide analysis of Peak II (or 
hexasaccharide 7) confirmed the presence of a μUA-[N-35S]GlcNS6S product, consistent 
with our conclusion that Peak II carried two 6-O-sulfo groups (Fig 5C and 5D). Our data 
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suggest that 6-OST-1 and 6-OST-3 kinetically prefer to sulfate the reducing end especially 
when a GlcNAc residue is located closer to the reducing end. We also conducted a 
disaccharide analysis of the 35S-labeled peak eluted at 35 min that resulted from the partial 
6-O-sulfation of hexasaccharide 3 with 6-OST-1 alone (as shown in Supplementary Fig 2A). 
As when using a mixture of 6-OST-1 and -3, the 6-O-sulfo group was determined to be at 
the GlcNAc residue (data not shown).
To examine whether partial 6-O-sulfation occurs at a GlcNS residue located closer to the 
reducing end, we employed another hexasaccharide substrate (hexasaccharide 4). Unlike 
hexasaccharide 3, this substrate carries a GlcNS residue that is closer to the reducing end, 
and it was 35S-labeled at the N-sulfo position. Again, two 35S-labeled peaks, designated as 
Peaks III and IV, were observed at 35 and 48 min after four hours incubation with a mixture 
of 6-OST-1 and -3 (Supplementary Fig 3A). The disaccharide analysis of Peak III revealed 
the presence of two disaccharides, μUA-[N-35S]GlcNS and μUA-[N-35S]GlcNS6S with a 
ratio of 1:2 (Supplementary Fig 3C). Our results suggest that Peak III is a mixture of two 
hexasaccharides: one hexasaccharide (the major product) carried the 6-O-sulfo group at the 
GlcNS residue, and another hexasaccharide (the minor product) carried the 6-O-sulfo group 
at the GlcNAc residue. Peak IV was expected to carry two 6-O-sulfo groups because it was 
eluted at around 48 min on DEAE-HPLC. The results of using hexasaccharide 4 as a 
substrate suggest that the mixture of 6-OST-1 and -3 displayed a modest to minimal 
preference for the GlcNS residue when it is located closer to the reducing end.
A strategy for preparing selectively 6-O-sulfated hexasaccharides
It is difficult to prepare a hexasaccharide that carries a single 6-O-sulfo group by partial 
sulfation using a mixture of 6-OST-1 and -3 because a mixture of 6-O-sulfated products is 
obtained. We attempted to use an alternative strategy to achieve this goal. Taking the 
advantage of the fact that the mixture of 6-OST-1 and -3 sulfate short oligosaccharide 
substrates, we exploited the possibility of elongating oligosaccharides carrying 6-O-sulfo 
groups by KfiA and PmHS2. We started with 6-O-sulfated tetrasaccharide 6 and elongated it 
to hexasaccharides using bacterial glycosyltransferases (Fig 6). To demonstrate the utility of 
this approach, two hexasaccharides (hexasaccharide 8 and 9) were synthesized, which differ 
at the glucosamine residue closer to the nonreducing end: hexasaccharide 8 has a GlcNAc, 
and hexasaccharide 9 has a GlcNS residue. The final structures of hexasaccharide 8 and 9 
were determined by mass spectrometry. For example, ESI-MS analysis revealed the 
molecular mass of hexasaccharide 9 to be 1502.2 Da, equal to the calculated molecular mass 
(1502.2 Da) (Fig 7B). MS/MS analysis confirmed the position of the GlcNS residues in 9 
(Fig 7D) from the two characteristic daughter ions, Y3(m/z, 907) and B3 (m/z, 592.3), which 
are products of the cleavage of an internal glycosidic linkage. Taken together, our results 
suggest that the elongation approach allowed us to prepare partially 6-O-sulfated 
hexasaccharides.
We noted that significant desulfation occurred for hexasaccharide 9 while it underwent the 
ESI-MS analysis. To eliminate the possibility that hexasaccharide 9 is a mixture, an N-35S-
labeled hexasaccharide 9 was synthesized following an identical procedure. The 35S-labeled 
hexasaccharide 9 was eluted at 35 min on a DEAE-HPLC column (Supplementary Fig 4). 
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This retention time is consistent with a hexasaccharide carrying an N-sulfo and a 6-O-sulfo 
group.
Discussion
The long-term goal of our research is to develop an enzyme-based method to synthesize 
heparin and structurally defined HS oligosaccharides. A method for selectively placing a 6-
O-sulfo group represents an essential part of this initiative. 6-OST is present in three 
different isoforms (17, 27), and we have obtained purified recombinant 6-OST-1 and 6-
OST-3 in large quantities using E. coli expression. Previously, Smeds and colleagues 
concluded that the three isoforms have no distinguishable substrate specificities (20). 
Although preparing fully sulfated oligosaccharides using a mixture of 6-OST-1 and -3 has 
been accomplished by our lab (11), placing a 6-O-sulfo group in a specific position 
remained a challenge. In this study, we demonstrated the feasibility of placing a 6-O-sulfo 
group within an oligosaccharide using a combination of bacterial glycosyl transferases and 
6-OSTs. In our approach, we preassemble the 6-O-sulfo group on a tetrasaccharide. The 6-
O-sulfated tetrasaccharide can be then elongated to a hexasaccharide with high efficiency. 
Our study used a mixture of 6-OST-1 and -3 to carry out most of the experiments because 
we did not detect any difference in substrate specificities between 6-OST-1 alone vs a 
mixture of 6-OST-1 and -3, although the mixture may provide higher 6-O-sulfation capacity 
to avoid incomplete 6-O-sulfation. Nevertheless, we cannot rule out the possibility that 
subtle differences in substrate specificities among 6-OST isoforms exist at the 
polysaccharide level.
The results from our study also provide insights into the substrate specificities of 6-OSTs 
using synthetic oligosaccharide model substrates. As in previous reports, the enzymes were 
found to sulfate both GlcNAc and GlcNS residues (20). We observed that a trisaccharide is 
sufficiently long to serve as a sulfo group receptor. Furthermore, we observed that it is very 
difficult to obtain a hexasaccharide carrying a single 6-O-sulfo group simply by shortening 
the reaction time. Our results found that the combination of 6-OST-1 and -3 has a clear 
preference for sulfating the N-acetylated glucosamine residue closer to the reducing end of a 
hexasaccharide substrate. However, this preference was significantly reduced when this 
residue is replaced with a GlcNS residue. A report by Jemth and colleagues also 
demonstrated that 6-OSTs prefer to sulfate an internal glucosamine residue that is closer the 
reducing end using different oligosaccharide substrates (28).
In summary, we developed an enzyme-based method that can prepare oligosaccharides 
carrying fully 6-O-sulfo groups. Our method is also capable of introducing a single 6-O-
sulfo group followed by elongation of the oligosaccharides using bacterial glycosyl 
transferases. By doing so, we are able to introduce a 6-O-sulfo group to a glucosamine 
located in the middle of a target oligosaccharide. Although the 6-O-sulfated tetrasaccharide 
has only been extended to hexasaccharides in the current study, it is possible to further 
extend it to larger oligosaccharides (22). However, our method is unable to introduce a 6-O-
sulfo group at the glucosamine residue located closer to the nonreducing end when the 
reducing end glucosamine residues are devoid of 6-O-sulfation. It should be noted that HS 
6-O-sulfatases remove 6-O-sulfo group from HS in vivo (18,19). It could be possible to 
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modify fully 6-O-sulfated HS substrates by 6-O-sulfatases so that a 6-O-sulfo group remains 
at the glucosamine residue located at the nonreducing end. Given the important role of 6-O-
sulfation for the function of HS, our method should provide a powerful tool to synthesize 
structurally defined oligosaccharides to probe the structure and activity relationship of HS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. Structure of HS and 6-O-sulfation of HS
Panel A shows the chemical structure of heparan sulfate. The structures of glucuronic acid 
(GlcUA) and iduronic acid (IdoUA) are indicated. Panel B shows the enzymatic reaction 
catalyzed by 6-OST, where PAPS is a sulfo donor. The modification site is highlighted.
Liu and Liu Page 12













Fig 2. Structural characterization of N-sulfo hexasaccharide 3 and hexasaccharide 4
Panel A shows the mass spectrometry spectrum of hexasaccharide 3. Panel B shows the 
mass spectrometry spectrum of hexasaccharide 4. Panel C shows MS/MS of hexasaccharide 
3 (precursor ion selection at m/z 710.1). The fragmentation pattern is depicted at the top. 
Panel D shows MS/MS of hexasaccharide 4 (precursor ion selection at m/z 710.1). The 
fragmentation pattern is depicted at the top. The product ions in the MS/MS data were 
labeled according to Domon-Costello nomenclature (26).
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Fig 3. Structural characterization of 6-O-sulfo trisaccharide 5 and 6-O-sulfo tetrasaccharide 6
Panel A shows the MS spectrum of 6-O-sulfo trisaccharide 5. Panel B shows the MS 
spectrum of 6-O-sulfo tetrasaccharide 6. Panel C shows MS/MS of 6-O-sulfo trisaccharide 5 
(precursor ion selection at m/z 907.4). The fragmentation pattern is depicted at the top. Panel 
D shows MS/MS of 6-O-sulfo tetrasaccharide 6 (precursor ion selection at m/z 1083.5). The 
fragmentation pattern is depicted at the top. The product ions in the MS/MS data were 
labeled according to Domon-Costello nomenclature (26).
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Fig 4. Preparation of 6-O-sulfo hexasaccharides with different reaction time
Panel A shows the HPLC chromatogram of [N-35S]-labeled hexasaccharide 3 using a 
DEAE-HPLC column. Panel B shows the HPLC chromatogram of [N-35S]sulfo-labeled 
hexasaccharide 3 using a DEAE-HPLC column after a one-hour reaction time. Panel C 
shows the HPLC chromatogram of [N-35S]sulfo-labeled hexasaccharide 3 using a DEAE-
HPLC column after a four-hour reaction time. Panel D shows the HPLC chromatogram of 
N-[35S]sulfo-labeled hexasaccharide 3 using a DEAE-HPLC column after 24 hours of 
reaction time.
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Fig 5. Determination of the structures of 6-O-sulfo hexasaccharides
Panel A shows the HPLC chromatogram of the disaccharide analysis of Peak I. The 
enzymatic reaction involved in the disaccharide analysis of Peak I is shown in Panel B. 
Panel C shows the HPLC chromatogram of the disaccharide analysis of Peak II. Panel D 
shows the reaction involved in the disaccharide analysis of Peak II. The radioactively 
labeled N-sulfo group is colored in red. The disaccharide products from heparin lyases 
degradation are shown in Panel B and D. The disaccharide analysis was performed on a C18-
HPLC column under RPIP-HPLC conditions. The eluent was monitored by an on-line 
radioactive detector. Under these conditions, the nonradioactively labeled disaccharide 
(ΔUA-GlcNAc6R shown in Panel B and D) could not be detected.
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Fig 6. Scheme for the synthesis of monosulfated hexasaccharides 8 and 9
Tetrasaccharide 2 was first 6-O-sulfated to yield the 6-O-sulfated tetrasaccharide. The 
tetrasaccharide was then elongated by KfiA and pmHS2 using different monosaccharide 
donors, UDP-GlcNAc and UDP-trifluoroacetylglucosamine (UDP-GlcNTFA). To convert 
the GlcNTFA to a GlcNS in hexasaccharide 9, the hexasaccharide was subjected to mild 
base treatment followed by N-sulfation with NST.
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Fig 7. Structural characterization of 6-O-sulfo hexasaccharides 8 and 9
Panel A shows the mass spectrometry spectrum of hexasaccharide 8. Panel B shows the 
mass spectrometry spectrum of hexasaccharide 9. Additional molecular ions are labeled as 1 
and 2, where 1 is 473.2 [M-SO3-3H]3− and 2 is 710.0 [M-SO3-2H]2−. Panel C shows 
MS/MS of hexasaccharide 8 (precursor ion selection at m/z 1462.4). The fragmentation 
pattern is depicted at the top. Panel D shows MS/MS of hexasaccharide 9 (precursor ion 
selection at m/z 750.0). The fragmentation pattern is depicted at the top. The product ions in 
the MS/MS data were labeled according to Domon-Costello nomenclature (26).
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Table 1
List of oligosaccharide substrates and products
Compound Structure Calc. MW Observed MW
Trisaccharide 1


























Rf represents the fluorous tag.
b
Both Hexasaccharides 3 and 4 have an identical molecular mass. The location of the N-sulfo group in each hexasaccharide was determined by a 
tandem MS method as shown in Fig 2.
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